Investors will be hoping for strength from Avid Bioservices as it approaches its next earnings release. On that day, Avid Bioservices is projected to report earnings of $0.05 per share, which would represent year-over-year growth of 400%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $28 million, up 28.38% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $0.28 per share and revenue of $117.1 million, which would represent changes of +366.67% and +22.15%, respectively, from the prior year.